TDMS No. 20009 - 04	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]	Date Report Requested: 05/27/2011
Test Type: CHRONIC	beta-Picoline	Time Report Requested: 09:52:36
Route: DOSED WATER	CAS Number: 108-99-6	First Dose M/F: 11/09/04 / 11/08/04
Species/Strain: MICE/B6C3F1		Lab: BAT

F2_M3

C Number:	C20009
Lock Date:	05/05/2008
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	2.4.1.0_004
PWG Approval Date:	12/14/2010

TDMS No. 20009 - 04	P18: INCIDENCE RAT	Date Report Requested: 05/27/2011				
Test Type: CHRONIC		beta-P	icoline		Time Report Requested: 09:52:36	
Route: DOSED WATER		CAS Numbe	er: 108-99-6		First Dose M/F: 11/09/04 / 11/08/04	
Species/Strain: MICE/B6C3F1						
B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l		
Disposition Summary						
Animals Initially In Study	50	50	50	50		
Early Deaths			•••	••		
Moribund Sacrifice	6	4	8	7		
Natural Death	20	20	15	10		
Survivors						
Terminal Sacrifice	24	26	27	33		
Animals Examined Microscopically	50	50	50	50		
ALIMENTARY SYSTEM						
Esophagus	(50)	(50)	(50)	(50)		
Gallbladder	(36)	(33)	(39)	(42)		
Degeneration, Hyaline		1 [3.0]				
Inflammation, Chronic Active			1 [3.0]			
Intestine Large, Cecum	(35)	(34)	(36)	(40)		
Intestine Large, Colon	(40)	(40)	(41)	(40)		
Intestine Large, Rectum	(39)	(38)	(42)	(41)		
Intestine Small, Duodenum	(36)	(31)	(35)	(40)		
Intestine Small, Ileum	(36)	(35)	(39)	(40)		
Intestine Small, Jejunum	(35)	(32)	(37)	(40)		
Diverticulum	1					
Peyer's Patch, Hyperplasia, Lymphoid		1 [3.0]				
Liver	(50)	(50)	(50)	(50)		
Angiectasis	1 [2.0]	3 [2.3]	2 [2.0]	3 [2.7]		
Basophilic Focus	10	12	15	7		
Clear Cell Focus	15	19	16	9		
Congestion				1 [2.0]		
Cyst				1 [2.0]		
Eosinophilic Focus	18	16	19	10		
Fatty Change		1 [3.0]				
Hematopoietic Cell Proliferation	1 [2.0]					
Inflammation, Chronic			2 [1.5]	1 [4.0]		
Inflammation, Chronic Active				2 [1.0]		
Mineralization			1 [2.0]			

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

TDMS No. 20009 - 04	P18: INCIDENCE RAT	Date Report Requested: 05/27/201			
Test Type: CHRONIC		beta-P	icoline		Time Report Requested: 09:52:36
Route: DOSED WATER		CAS Numbe	er: 108-99-6		First Dose M/F: 11/09/04 / 11/08/04
Species/Strain: MICE/B6C3F1					Lab: BAT
B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l	
Mixed Cell Focus	5	4	5	4	
Necrosis	5 [2.8]	6 [3.0]	6 [2.7]	4 [3.0]	
Mesentery	(7)	(1)	(1)	(1)	
Inflammation, Chronic Active	1 [4.0]	()	()		
Fat, Necrosis	5 [2.0]		1 [2.0]	1 [2.0]	
Pancreas	(49)	(48)	(48)	(49)	
Atrophy	1 [1.0]	(10)	(10)	(13)	
Necrosis	1 [1.0]			1 [2.0]	
Salivary Glands	(50)	(50)	(50)	(50)	
Stomach, Forestomach	(30)	(47)	(47)	(47)	
Hyperplasia, Squamous				(47) 1 [4.0]	
Ulcer	2 [2.0]	4 [2.3]	3 [2.7]		
	5 [2.2]	3 [2.7]	4 [3.0]	1 [2.0]	
Stomach, Glandular	(42)	(45)	(43)	(45)	
Mineralization		2 [1.0]	4 [4 0]		
Necrosis	4 [0, 0]	0.14.51	1 [1.0]		
Ulcer	1 [2.0]	2 [1.5]	(10)	()	
Tooth	(35)	(41)	(42)	(41)	
Dysplasia	35	41	42	41	
CARDIOVASCULAR SYSTEM					
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	12 [1.0]	17 [1.2]	7 [1.0]	4 [1.3]	
Inflammation, Suppurative	2 [2.5]		[]	.[]	
Mineralization	1 [1.0]	1 [2.0]	1 [2.0]	1 [1.0]	
Necrosis	. []	1 [2.0]	1 [2.0]	. []	
Thrombosis	2 [2.5]	2 [3.0]	1 [2.0]		
Artery, Inflammation, Chronic Active	2 [۲.0]	2 [0.0]	1 [3.0]	2 [3.0]	
			. [0.0]	2 [0.0]	
ENDOCRINE SYSTEM					
Adrenal Cortex	(49)	(48)	(50)	(48)	
Atrophy		1 [3.0]			
Hyperplasia	10 [2.0]	8 [2.0]	10 [2.0]	5 [2.2]	
Hypertrophy	12 [2.1]	14 [2.0]	14 [2.1]	17 [1.9]	

TDMS N	o. 20009	- 04
--------	-----------------	------

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/27/2011 AVERAGE SEVERITY GRADES[b]

est Type: CHRONIC		beta-P	• •		Time Report Requested: 09:52:36
Route: DOSED WATER		First Dose M/F: 11/09/04 / 11/08/04			
Species/Strain: MICE/B6C3F1		CAS Numbe	Lab: BAT		
B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l	
		4 [0 0]			
Subcapsular, Hyperplasia	(10)	1 [2.0]	(50)	(40)	
Adrenal Medulla	(49)	(47)	(50)	(48)	
Hyperplasia	1 [2.0]	1 [2.0]	1 [2.0]	(10)	
Islets, Pancreatic	(49)	(48)	(48)	(49)	
Hyperplasia		1 [3.0]	2 [2.0]		
Parathyroid Gland	(37)	(39)	(44)	(31)	
Pituitary Gland	(47)	(49)	(49)	(49)	
Thrombosis	1 [4.0]				
Pars Distalis, Hyperplasia	1 [3.0]		2 [2.5]		
Thyroid Gland	(49)	(50)	(49)	(49)	
GENITAL SYSTEM					
Coagulating Gland	(2)	(0)	(0)	(0)	
Inflammation, Suppurative	1 [3.0]	(-)	(-)	(-)	
Epididymis	(50)	(50)	(50)	(49)	
Granuloma Sperm	()	1 [3.0]	()	2 [1.5]	
Mineralization		[]		1 [2.0]	
Preputial Gland	(50)	(50)	(50)	(50)	
Cyst	()	()	()	1 [3.0]	
Inflammation, Chronic Active	3 [2.7]	3 [3.0]	4 [3.5]	1 [1.0]	
			(48)	(50)	
Prostate	(50)	(30)	(+0)	(30)	
Prostate Hyperplasia	(50)	(50) 1 [2.0]	(40)	(50)	
Hyperplasia		1 [2.0]			
Hyperplasia Inflammation, Suppurative	(50) 4 [2.8]		2 [3.0]	1 [2.0]	
Hyperplasia Inflammation, Suppurative Inflammation, Chronic Active	4 [2.8]	1 [2.0]	2 [3.0] 1 [2.0]	1 [2.0]	
Hyperplasia Inflammation, Suppurative Inflammation, Chronic Active Seminal Vesicle			2 [3.0] 1 [2.0] (49)	1 [2.0] (47)	
Hyperplasia Inflammation, Suppurative Inflammation, Chronic Active Seminal Vesicle Amyloid Deposition	4 [2.8] (47)	1 [2.0]	2 [3.0] 1 [2.0]	1 [2.0]	
Hyperplasia Inflammation, Suppurative Inflammation, Chronic Active Seminal Vesicle Amyloid Deposition Inflammation, Suppurative	4 [2.8]	1 [2.0] (48)	2 [3.0] 1 [2.0] (49) 2 [3.0]	1 [2.0] (47) 1 [3.0]	
Hyperplasia Inflammation, Suppurative Inflammation, Chronic Active Seminal Vesicle Amyloid Deposition	4 [2.8] (47)	1 [2.0]	2 [3.0] 1 [2.0] (49)	1 [2.0] (47)	

a - Number of animals examined microscopically at site and number of animals with lesion

0 mg/l (50) (2) 1 [4.0]	AVERAGE SEVEI beta-P CAS Numbe 312.5 mg/l 1 [2.0] (50)	icoline	1250 mg/l 1 [2.0]	Time Report Requested: 09:52:36 First Dose M/F: 11/09/04 / 11/08/04 Lab: BAT
(50) (2) 1 [4.0]	312.5 mg/l 1 [2.0] (50)	625 mg/l 1 [2.0]	·	
(50) (2) 1 [4.0]	1 [2.0]	1 [2.0]	·	
(2) 1 [4.0]	(50)		1 [2.0]	
(2) 1 [4.0]	(50)	(48)		
(2) 1 [4.0]		(48)		
(2) 1 [4.0]		(48)		
1 [4.0]			(50)	
1 [4.0]		1 [3.0]		
	(1)	(0)	(2)	
(50)	(40)	(40)	(50)	
(50)	(49)	(49)	(50)	
	(45)	1 [3.0]		
(45)	(45)	(43)	(45)	
		4 [4 0]	1 [4.0]	
()	(45)			
		(47)	(46)	
	1 [2.0]			
(41)	(42)	(48)	(47)	
(50)	(50)	(50)	(50)	
1 [2.0] 2 [4.0]	1 [4.0]			
(50)	(50)	(50)	(50)	
(1)	(0)		(0)	
(50)	(50)	(50)	(50)	
	(46) 1 [4.0] 2 [2.0] (41) (50) 1 [2.0]	$ \begin{array}{cccc} (46) & (48) \\ 1 & [4.0] & 1 & [2.0] \\ 2 & [2.0] \\ (41) & (42) \end{array} \\ \begin{array}{c} (50) & (50) \\ 1 & [2.0] \\ 2 & [4.0] & 1 & [4.0] \end{array} \\ \begin{array}{c} (50) & (50) \\ 1 & [4.0] \end{array} \\ \begin{array}{c} (50) & (50) \\ (1) & (0) \end{array} \end{array} $	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

TDMS No. 20009 - 04	P18: INCIDENCE RAT	Date Report Requested: 05/27/2011 Time Report Requested: 09:52:36			
Test Type: CHRONIC					
Route: DOSED WATER		CAS Number	er: 108-99-6		First Dose M/F: 11/09/04 / 11/08/04
Species/Strain: MICE/B6C3F1					Lab: BAT
B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l	
Hemorrhage		1 [2.0]			
Glial Cell, Pigmentation	1 [1.0]				
RESPIRATORY SYSTEM					
Lung	(50)	(50)	(50)	(50)	
Hemorrhage	2 [1.5]	1 [1.0]			
Inflammation, Suppurative		1 [4.0]			
Inflammation, Granulomatous	1 [3.0]	1 [3.0]			
Thrombosis			1 [2.0]	2 [1.0]	
Alveolar Epithelium, Hyperplasia	4 [1.8]	6 [1.2]	6 [2.7]	7 [1.7]	
Alveolus, Infiltration Cellular, Histiocyte	2 [2.0]	1 [3.0]	3 [2.7]	2 [2.5]	
Bronchiole, Hyperplasia	1 [1.0]		1 [2.0]		
Nose	(50)	(50)	(50)	(50)	
Inflammation, Suppurative	4 [1.5]	9 [1.1]	9 [1.0]	6 [1.7]	
Olfactory Epithelium, Atrophy	3 [1.3]	4 [1.3]	8 [1.5]	7 [1.6]	
Olfactory Epithelium, Metaplasia, Respiratory	8 [1.0]	12 [1.1]	30 [1.3]	41 [1.7]	
Respiratory Epithelium, Hyperplasia	18 [1.3]	23 [1.3]	23 [1.3]	17 [1.6]	
Pleura	(0)	(1)	(0)	(1)	
Trachea	(47)	(49)	(45)	(49)	
SPECIAL SENSES SYSTEM					
Еуе	(36)	(39)	(43)	(40)	
Degeneration	1 [4.0]	1 [4.0]	1 [4.0]	1 [4.0]	
Inflammation, Suppurative				1 [3.0]	
Cornea, Inflammation, Chronic Active			1 [2.0]		
Retina, Hemorrhage, Chronic	1 [3.0]		1 [3.0]		
Harderian Gland	(46)	(47)	(46)	(47)	
Hyperplasia	1 [3.0]	1 [2.0]		4 [1.5]	
Inflammation, Chronic			1 [3.0]		

URINARY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

TDMS	No.	20009	- 04
------	-----	-------	------

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/27/2011 AVERAGE SEVERITY GRADES[b]

est Type: CHRONIC Route: DOSED WATER Species/Strain: MICE/B6C3F1		beta-P CAS Numbe	Time Report Requested: 09:52:36 First Dose M/F: 11/09/04 / 11/08/04 Lab: BAT		
36C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l	
Kidney	(50)	(50)	(50)	(49)	
Amyloid Deposition			1 [2.0]		
Cyst	1 [2.0]				
Hydronephrosis	1 [3.0]	2 [2.0]	1 [3.0]	2 [2.5]	
Infarct		1 [2.0]	1 [3.0]		
Inflammation, Suppurative	2 [3.0]			1 [3.0]	
Metaplasia, Osseous	4 [1.3]	4 [1.0]	1 [1.0]	4 [1.0]	
Mineralization	3 [2.0]	2 [1.0]	2 [2.0]	1 [2.0]	
Nephropathy	43 [2.0]	49 [1.9]	49 [2.2]	49 [2.1]	
Thrombosis	1 [3.0]				
Artery, Inflammation, Chronic Active		1 [3.0]	1 [3.0]		
Papilla, Necrosis	2 [4.0]		1 [3.0]	2 [3.0]	
Renal Tubule, Hyperplasia			1 [2.0]		
Renal Tubule, Hypertrophy		1 [2.0]			
Renal Tubule, Pigmentation	1 [4.0]			1 [3.0]	
Urethra	(3)	(3)	(5)	(3)	
Inflammation, Suppurative	1 [3.0]	3 [2.3]	3 [2.3]	1 [2.0]	
Urinary Bladder	(45)	(45)	(45)	(46)	
Hemorrhage	1 [3.0]	1 [2.0]			
Inflammation, Suppurative	1 [1.0]				
Inflammation, Chronic			1 [1.0]		

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04	P18: INCIDENCE RAT	Date Report Requested: 05/27/2017					
Test Type: CHRONIC		beta-P	icoline		Time Report Requested: 09:52:36		
Route: DOSED WATER		CAS Numbe	er: 108-99-6		First Dose M/F: 11/09/04 / 11/08/04		
Species/Strain: MICE/B6C3F1							
B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l			
Disposition Summary							
Animals Initially In Study	50	50	50	50			
Early Deaths							
Moribund Sacrifice	4	3	1	4			
Natural Death	8	15	14	13			
Survivors							
Natural Death			1				
Terminal Sacrifice	38	32	34	33			
Animals Examined Microscopically	50	50	50	50			
ALIMENTARY SYSTEM							
Esophagus	(50)	(49)	(49)	(50)			
Gallbladder	(43)	(36)	(36)	(35)			
Degeneration, Hyaline			1 [4.0]	1 [3.0]			
Intestine Large, Cecum	(44)	(36)	(38)	(39)			
Intestine Large, Colon	(44)	(35)	(40)	(38)			
Intestine Large, Rectum	(43)	(35)	(37)	(38)			
Intestine Small, Duodenum	(42)	(35)	(36)	(37)			
Lymphangiectasis	()	(00)	1 [3.0]	(01)			
Intestine Small, Ileum	(44)	(36)	(37)	(37)			
Inflammation, Acute	(77)	(00)	1 [4.0]	(07)			
Intestine Small, Jejunum	(43)	(35)	(37)	(38)			
Inflammation, Granulomatous	(40)	1 [3.0]	(37)	(00)			
Inflammation, Acute		1 [3.0]	1 [4.0]				
Liver	(49)	(50)		(50)			
			(50)	(50) 5 [2 4]			
Angiectasis	3 [3.3]	3 [3.0]	6 [2.3]	5 [2.4]			
Basophilic Focus	4	2	1	6			
Clear Cell Focus	3	2	6	4 [0.0]			
Congestion		4.0		1 [3.0]			
Eosinophilic Focus	11	10	14	15			
Fatty Change		4 [2.8]	1 [3.0]	2 [2.5]			
Hematopoietic Cell Proliferation		1 [1.0]					
Mixed Cell Focus				2			
Necrosis	4 [2.8]	2 [3.0]	3 [3.3]	2 [2.0]			

TDMS	No.	20009	- 04
------	-----	-------	------

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 05/27/2011 AVERAGE SEVERITY GRADES[b]

Test Type: CHRONIC Route: DOSED WATER Species/Strain: MICE/B6C3F1		Time Report Requested: 09:52:36 First Dose M/F: 11/09/04 / 11/08/04 Lab: BAT			
B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l	
Tension Lipidosis	1 [2.0]	1 [2.0]		2 [2.0]	
Thrombosis		1 [3.0]			
Mesentery	(8)	(16)	(16)	(9)	
Fat, Hemorrhage		1 [4.0]			
Fat, Necrosis	7 [2.0]	14 [2.0]	13 [2.0]	8 [2.0]	
Pancreas	(48)	(42)	(46)	(45)	
Atrophy	2 [3.0]		2 [1.0]	1 [1.0]	
Thrombosis		1 [4.0]			
Duct, Cyst	1 [4.0]	1 [2.0]			
Salivary Glands	(50)	(47)	(47)	(50)	
Inflammation, Chronic				1 [2.0]	
Necrosis	1 [4.0]				
Stomach, Forestomach	(47)	(43)	(45)	(47)	
Hyperplasia, Squamous		1 [2.0]	3 [2.0]	3 [2.7]	
Ulcer		1 [2.0]	1 [3.0]		
Stomach, Glandular	(45)	(39)	(41)	(41)	
Dysplasia			1 [2.0]		
Hyperplasia		1 [3.0]			
Mineralization	2 [2.0]	2 [2.0]	1 [2.0]		
Tongue	(0)	(0)	(0)	(1)	
Tooth	(0)	(1)	(2)	(9)	
Dysplasia			2	9	
CARDIOVASCULAR SYSTEM					
Blood Vessel	(2)	(3)	(1)	(0)	
Mineralization	2 [3.0]	3 [3.0]	1 [3.0]		
Heart	(50)	(50)	(49)	(50)	
Cardiomyopathy	4 [1.0]	1 [2.0]	7 [1.1]	3 [1.0]	
Inflammation, Suppurative	1 [3.0]	1 [3.0]		1 [3.0]	
Mineralization	1 [3.0]	4 [1.5]	1 [2.0]		
Necrosis		1 [2.0]			
Thrombosis	2 [3.0]	1 [4.0]			
Artery, Inflammation, Chronic Active				1 [3.0]	
Capillary, Hyperplasia		1 [2.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04	P18: INCIDENCE RAT	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]				
Test Type: CHRONIC		Time Report Requested: 09:52:36 First Dose M/F: 11/09/04 / 11/08/04 Lab: BAT				
Route: DOSED WATER Species/Strain: MICE/B6C3F1 B6C3F1 MICE FEMALE						
	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l		
ENDOCRINE SYSTEM						
Adrenal Cortex	(49)	(45)	(46)	(50)		
Hyperplasia	2 [2.0]			1 [2.0]		
Hypertrophy	1 [3.0]	1 [3.0]		1 [2.0]		
Vacuolization Cytoplasmic	. []	[]	1 [3.0]	[]		
Adrenal Medulla	(49)	(45)	(46)	(50)		
Hyperplasia	(10)	1 [1.0]	(10)	(00)		
Islets, Pancreatic	(48)	(41)	(45)	(45)		
Hyperplasia	(-0)	(11)	1 [2.0]	1 [3.0]		
Parathyroid Gland	(38)	(34)	(40)	(41)		
-	(30)	(34)		(+1)		
Hyperplasia Bituitany Cland	(50)		2 [2.0]	(40)		
Pituitary Gland	(50)	(46)	(47)	(46)		
Pars Distalis, Angiectasis	3 [2.3]	1 [2.0]		1 [2.0]		
Pars Distalis, Hyperplasia	8 [2.0]	14 [2.1]	13 [2.3]	7 [2.4]		
Thyroid Gland	(48)	(45)	(45)	(49)		
Cyst				2 [2.5]		
Follicular Cell, Hyperplasia	1 [2.0]			1 [2.0]		
Follicular Cell, Hypertrophy			1 [2.0]			
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM				·		
Clitoral Gland	(50)	(50)	(48)	(50)		
Ovary	(49)	(48)	(48)	(47)		
Cyst	5 [2.2]	5 [3.8]	5 [3.0]	4 [3.0]		
Thrombosis	~ []	- [0:0]	2 [4.0]	4 [4.0]		
Uterus	(49)	(47)	(49)	(49)		
Angiectasis	(10)	1 [4.0]	(10)	(10)		
Inflammation, Acute		נסיבו י		2 [3.5]		

TDMS No. 20009 - 04	P18: INCIDENCE RAT	 Date Report Requested: 05/27/201 Time Report Requested: 09:52:36 				
Test Type: CHRONIC						
Route: DOSED WATER		CAS Numbe	er: 108-99-6		First Dose M/F: 11/09/04 / 11/08/04	
Species/Strain: MICE/B6C3F1						
B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l		
Necrosis				1 [4.0]		
Thrombosis	1 [3.0]		1 [4.0]	1 [4.0]		
Endometrium, Hyperplasia, Cystic	33 [3.2]	29 [3.1]	33 [3.4]	37 [3.0]		
Endometrium, Hyperplasia, Cystic	55 [5.2]	29 [3.1]	55 [5.4]	57 [5.0]		
HEMATOPOIETIC SYSTEM						
Bone Marrow	(49)	(46)	(48)	(49)		
Angiectasis				1 [2.0]		
Lymph Node	(6)	(8)	(6)	(8)		
Lumbar, Angiectasis	1 [3.0]					
Lumbar, Hemorrhage			1 [3.0]			
Mediastinal, Hyperplasia, Lymphoid	1 [2.0]	1 [2.0]				
Pancreatic, Ectasia	1 [4.0]					
Renal, Ectasia	1 [4.0]	1 [3.0]	1 [4.0]			
Lymph Node, Mandibular	(48)	(42)	(47)	(47)		
Hyperplasia, Lymphoid	(),		1 [3.0]			
Lymph Node, Mesenteric	(46)	(38)	(45)	(46)		
Angiectasis	()	()	()	1 [3.0]		
Hemorrhage			1 [3.0]	1 [3.0]		
Spleen	(46)	(42)	(45)	(46)		
Hematopoietic Cell Proliferation	4 [2.8]	3 [3.3]	5 [2.2]	1 [3.0]		
Hyperplasia, Lymphoid	+ [2:0]	0 [0.0]	0[2.2]	1 [2.0]		
Thrombosis		1 [3.0]		، اح.0]		
Thymus	(45)		(19)	(17)		
•	(45)	(44)	(48)	(47)		
Amyloid Deposition			1 [2.0]	4 [0 0]		
Hyperplasia, Lymphoid			1 [2.0]	1 [3.0]		
INTEGUMENTARY SYSTEM						
Mammary Gland	(50)	(49)	(49)	(48)		
Hyperplasia	1 [2.0]					
Skin	(50)	(50)	(50)	(50)		
Hyperplasia, Squamous		1 [4.0]				
Inflammation, Acute			1 [3.0]			
Inflammation, Chronic Active		2 [4.0]				

TDMS No. 20009 - 04	P18: INCIDENCE RAT	Date Report Requested: 05/27/2011 Time Report Requested: 09:52:36			
Test Type: CHRONIC					
Route: DOSED WATER		CAS Numbe	er: 108-99-6		First Dose M/F: 11/09/04 / 11/08/04 Lab: BAT
Species/Strain: MICE/B6C3F1					
B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l	
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(50)	(50)	(50)	
Hyperostosis				1 [3.0]	
Skeletal Muscle	(1)	(0)	(0)	(1)	
NERVOUS SYSTEM					
Brain	(50)	(47)	(47)	(50)	
Hemorrhage	()	1 [2.0]	()	1 [1.0]	
Necrosis		1 [1.0]			
Peripheral Nerve	(1)	(0)	(0)	(1)	
Spinal Cord	(1)	(0)	(0)	(1)	
RESPIRATORY SYSTEM					
Lung	(50)	(50)	(49)	(50)	
Hemorrhage		()	(- /	1 [1.0]	
Inflammation, Acute			1 [3.0]	r - 1	
Inflammation, Chronic Active		1 [2.0]	[]		
Mineralization	1 [4.0]	3 [3.0]	2 [2.0]		
Alveolar Epithelium, Hyperplasia	2 [1.5]	4 [2.5]	3 [1.3]	8 [1.8]	
Alveolus, Infiltration Cellular, Histiocyte	2 [2.0]	1 [3.0]	1 [2.0]	L - J	
Bronchiole, Hyperplasia	L - J	r	3 [2.0]	1 [2.0]	
Nose	(49)	(44)	(49)	(47)	
Inflammation, Suppurative	1 [1.0]	· /	x - /	1 [1.0]	
Olfactory Epithelium, Atrophy	1 [1.0]	2 [1.0]	2 [1.0]	7 [1.3]	
Olfactory Epithelium, Metaplasia, Respiratory		2 [1.0]	7 [1.0]	14 [1.2]	
Respiratory Epithelium, Hyperplasia	7 [1.0]	2 [1.0]	6 [1.0]	13 [1.2]	
Pleura	(0)	(0)	(0)	(1)	
Trachea	(47)	(41)	(45)	(44)	
Mineralization	1 [3.0]	1 [3.0]	(-)	× -7	

TDMS No. 20009 - 04	P18: INCIDENCE RAT	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]				
Test Type: CHRONIC		Time Report Requested: 09:52:36				
Route: DOSED WATER		CAS Numb	er: 108-99-6		First Dose M/F: 11/09/04 / 11/08/04	
Species/Strain: MICE/B6C3F1 B6C3F1 MICE FEMALE						
	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l		
SPECIAL SENSES SYSTEM						
Eye	(43)	(35)	(36)	(39)		
Cataract	1 [3.0]		()			
Degeneration	1 [4.0]		1 [3.0]	1 [4.0]		
Cornea, Inflammation, Acute	1 [1.0]	1 [2.0]	[]	r - 1		
Cornea, Inflammation, Chronic Active	L - J			1 [3.0]		
Harderian Gland	(45)	(41)	(43)	(47)		
Hyperplasia	5 [2.4]	2 [2.0]	1 [2.0]	1 [3.0]		
Inflammation, Chronic	- []	-[]	1 [1.0]	.[]		
Zymbal's Gland	(0)	(0)	(0)	(1)		
URINARY SYSTEM						
Kidney	(49)	(47)	(48)	(49)		
Amyloid Deposition	1 [3.0]	1 [2.0]	1 [3.0]			
Hydronephrosis		1 [2.0]				
Inflammation, Suppurative	1 [2.0]			1 [2.0]		
Metaplasia, Osseous		1 [1.0]	1 [1.0]			
Mineralization	3 [2.0]	2 [1.5]	1 [3.0]	2 [2.5]		
Nephropathy	29 [1.4]	16 [1.6]	25 [1.5]	30 [1.6]		
Renal Tubule, Necrosis	2 [2.5]	3 [2.7]	1 [2.0]	2 [3.5]		
Urinary Bladder	(44)	(37)	(39)	(41)		
Inflammation, Chronic		X- /	()	1 [2.0]		

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion